Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sandoz Climbs 'Pyramid' To Reach Biosimilar Success

Executive Summary

Biosimilars have turned drug development 'upside down,' where analytical confirmation outweighs clinical – a paradigm shift that must not only be embraced by the biopharmaceutical industry, but the prescribing community if US market for those products is going to be successful.


Related Content

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales
Edging Toward Interchangeability in Biosimilars
Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
'Uncomfortable' Panel Backs Amgen Biosimilar, But Uphill Battle To Sway Docs, Public
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Novartis/Sandoz make history with 1st US biosimilar Zarxio


Related Companies